The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
Over the course of treatment, patients with relapsed/refractory acute myeloid leukemia (AML) may acquire new TP53 mutations, making ongoing monitoring for mutations crucial. “New novel therapies ...
Patients with myelofibrosis (MF) with single-hit mutations had similar outcomes to patients with wild-type TP53. People with myelofibrosis (MF) who undergo hematopoietic stem cell transplantation ...
Speed and sensitivity touted as proof of its utility as a prognostic tool. Researchers at Asuragen and Johns Hopkins University School of Medicine report that an assay based on Asuragen’s NPM1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback